Drug intelligence / Profile preview

BSC2301

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

BSC2301 is a preclinical-stage small molecule payload developed by **BiSiChem** for use in **antibody-drug conjugates (ADCs)**. It is specifically designed for the treatment of **autoimmune diseases**. The compound serves as the effector component that is conjugated to a targeting antibody, allowing for the selective delivery of the therapeutic agent to specific immune cells involved in disease pathology. BiSiChem utilizes its proprietary platform to develop novel payloads and bi-specific small molecules to improve the therapeutic index of targeted treatments for inflammatory and autoimmune conditions.

Other names: BSC2301BSC-2301BSC 2301

Beyond the preview

Go deeper on BSC2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC2301.

Explore the full profile